Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Enliven Therapeutics (ELVN) Leases (2021 - 2026)

Enliven Therapeutics has reported Leases over the past 6 years, most recently at $290000.0 for Q1 2026.

  • Quarterly results put Leases at $290000.0 for Q1 2026, down 55.45% from a year ago — trailing twelve months through Mar 2026 was $290000.0 (down 55.45% YoY), and the annual figure for FY2025 was $383000.0, changed.
  • Leases reached $290000.0 in Q1 2026 per ELVN's latest filing, down from $383000.0 in the prior quarter.
  • Across five years, Leases topped out at $2.3 million in Q1 2022 and bottomed at $81000.0 in Q3 2024.
  • Median Leases over the past 5 years was $398000.0 (2023), compared with a mean of $510466.7.
  • The largest annual shift saw Leases plummeted 79.65% in 2024 before it skyrocketed 486.42% in 2025.
  • Over 5 years, Leases stood at $626000.0 in 2022, then tumbled by 48.88% to $320000.0 in 2023, then crashed by 74.69% to $81000.0 in 2024, then surged by 372.84% to $383000.0 in 2025, then dropped by 24.28% to $290000.0 in 2026.
  • Business Quant data shows Leases for ELVN at $290000.0 in Q1 2026, $383000.0 in Q4 2025, and $475000.0 in Q3 2025.